Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

GLP ‐ 1RA Semaglutide Delays the Progression of ADPKD Through Regulation of Glycolysis, Mitochondria Function and Ketosis
Wu, Jiao , Cheng, Alice, Harris, Peter C. , Zhou, Julie , Cheng, Alice Shasha, Zhou, Julie Xia, Harris, Peter C , Weimbs, Thomas , Li, Xiaogang

The FASEB Journal | August 15, 2025 | Volume: 39 | Issue: 16 | Pages: No page available

10.1096/fj.202501605r | PMID 40815122 Get It

ABSTRACT Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease that is caused by mutations in PKD genes. Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (GLP‐1RAs) are a class of medications that mimic the actions of the hormone GLP‐1, conferring beneficial effects on weight management and other metabolic conditions. However, whether GLP‐1RA plays a kidney‐protective action in ADPKD remains unknown. In this study, we define the role and mechanisms of one of the most popular GLP‐1RA agonists, Semaglutide, in ADPKD. We show that the expression of GLP‐1R is decreased in Pkd1 mutant renal epithelial cells and kidneys. Treatment with Semaglutide delays cyst growth in aggressive and long‐lasting Pkd1 mutant mouse models. Treatment with Semaglutide (1) decreases glucose uptake, ATP generation, and glycolysis, (2) deactivates PKD‐associated signaling pathways, including Rb, S6, and Stat3, resulting in a decrease in cell proliferation, (3) deactivates NF‐kB signaling pathways, resulting in a decrease in the expression of cytokines and the recruitment of macrophages, (4) normalizes mitochondrial morphology and function, (5) induces Pkd1 mutant renal epithelial cell death, (6) induces ketosis characterized by an increase in serum level of beta‐hydroxybutyrate (BHB) and the activation of AMPK, and (7) alleviates renal fibrosis through deactivation of TGF‐b signaling in Pkd1 mutant mouse kidneys. This study highlights the potential of GLP‐1R agonists as a novel therapeutic strategy for ADPKD treatment.
Cryopreservation of Autologous Adipose Tissue From Liposuction: A Review
Flaifel, Mariana, Cruickshank, K., Tahir, Aima , Menendez, Juan Pablo, Nicolas, Gregory N.

Plastic and Reconstructive Surgery - Global Open | August 15, 2025 | Volume: 13 | Issue: 8 | Pages: e7008

10.1097/gox.0000000000007008 | PMID 40821898 Get It

Background: Fat grafting is a common procedure in plastic and reconstructive surgery. It is associated with several disadvantages and complications, especially in patients undergoing recurrent procedures. Researchers are exploring the implications of cryopreserving adipose tissue and stem cells in plastic surgery. This article aimed to evaluate whether autologous fatty tissue and adipose-derived stem cells obtained through liposuction can be safely stored via cryopreservation for future surgical use. Methods: A comprehensive literature search was conducted across 3 databases, including PubMed, ScienceDirect, and Ovid MEDLINE, using specific keywords, yielding 75 articles. Studies that were not written in English or conducted in vitro were excluded. Only studies published in English within the last 5 years, and focusing on the use of cryopreservation of adipose tissue, were included. After review, a total of 22 articles met the inclusion criteria and were analyzed. Results: Cryopreserving adipose tissue and adipose-derived stem cells shows great potential in plastic surgery. Patient factors such as harvesting site, age, and obesity significantly impact the yield. The highest yield was obtained by harvesting from the abdomen and thigh. Additionally, cryopreservation requires cryoprotective agents, among which a combination of dimethyl sulfoxide and human serum albumin was most effective. Despite the advancement in cryoprotective agents, thawing adipose tissue results in cell death and impaired extracellular matrix integrity. However, cryopreserved stromal vascular fraction gel demonstrated fewer complications and better retention. Conclusions: The cryopreservation of adipose tissue and stromal vascular fraction gel demonstrates promising advancements for future applications in plastic surgery and regenerative medicine.
Re: “the challenges of measuring socioeconomic inequality in pharmacoepidemiology studies”
Wi, Chung‐Il , Shim, Dale, Juhn, Young J. , Wi, Chung-Ii

American Journal of Epidemiology | August 15, 2025 | Volume: 194 | Issue: 11 | Pages: 3394-3395

10.1093/aje/kwaf170 | PMID 40826906 Get It

AAV9-mediated KCNH2 suppression-replacement gene therapy in a transgenic rabbit model of type 1 short QT syndrome
Nimani, Saranda , Bains, Sahej , Alerni, Nicolò , Ördög, Balázs , Horváth, András , Matas, Lluis , Louradour, Julien , Giammarino, Lucilla , Tester, David J. , Beslac, Olgica, López, Rubén , Meier, Stefan , Christoforou, Nicolas , Barbieri, Miriam , Vashanthakumar, Varjany, Perez‐Feliz, Stefanie , Casalta, L.G. Garcia, Kim, C.S. John, Zhou, Wei , Ye, Dan , Jurgensen, Jacqulyn, Bego, Mariana G. , Keyes, Lisa R., Owens, Jane , Pinkstaff, Jason, Zehender, Manfred, Brunner, Michael, Heijman, Jordi , Casoni, Daniela , Brooks, Gabriel , Odening, Katja E. , Egle, Manuel , Barbieri, Miriam , Christoph, Jan , Brunner, Michael , Heijman, Jordi , Praz, Fabien , Haeberlin, Andreas , Ackerman, Michael J , Odening, Katja E , Bains, Sahej , Vashanthakumar, Varjany, Parodi, Chiara, Barry, Michael A. , Praz, Fabien , Ackerman, Michael

European Heart Journal | August 15, 2025 | Volume: 47 | Issue: 2 | Pages: 199-213

10.1093/eurheartj/ehaf660 | PMID 40884219 Get It

Abstract Background and Aims Type 1 short QT syndrome (SQT1) is a genetic channelopathy caused by gain-of-function variants in KCNH2, resulting in shortened cardiac repolarization and QT intervals, which predispose patients to ventricular arrhythmias and sudden cardiac death. This study aimed to investigate the therapeutic efficacy of KCNH2-specific suppression-and-replacement (KCNH2-SupRep) gene therapy in a transgenic rabbit model of SQT1. Methods KCNH2-SupRep was developed by combining a KCNH2-shRNA with its corresponding shRNA-immune KCNH2-cDNA into an AAV9 vector, delivered directly into the aortic root (1 × 1010 vg/kg). Therapeutic efficacy was evaluated in vivo by electrocardiogram, ex vivo by optical mapping, and at cellular levels by patch-clamp, calcium imaging, and qPCR in ventricular cardiomyocytes (VCMs). Results In vivo, KCNH2-SupRep normalized the heart rate-corrected QT interval (QTc) in SQT1 rabbits, without affecting repolarization heterogeneity. Ex vivo, KCNH2-SupRep corrected the action potential duration (APD90) and resolved the increased apicobasal APD90 heterogeneity observed in untreated (UT)-SQT1 hearts, supporting an antiarrhythmic effect, which was further validated by reduced re-entry formation in silico. At cellular levels, KCNH2-SupRep prolonged APD90 in VCMs from SupRep-SQT1 rabbits closer to wildtype levels compared with UT- and sham-SQT1. Additionally, KCNH2-SupRep restored the cellular surrogate of the electro-mechanical window and normalized IKr in nearly 50% of VCMs, in line with a 50%–60% suppression of the mutant KCNH2 transcript. Conclusions This proof-of-concept study is the first to demonstrate the efficacy of gene therapy for SQT1 in a medium-sized animal model. KCNH2-SupRep gene therapy successfully corrected the pathologic phenotype in vivo, ex vivo, and at cellular levels in transgenic SQT1 rabbits.
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial
Butler, Javed , Fioretti, Francesco , McMullan, Ciaran J. , Anstrom, Kevin J. , Barash, Irina , Bonaca, Marc P. , Borentain, Maria, Corda, Stefano , Gates, Davis, Lewis, Eldrin F. , Mentz, Robert J. , O’Connor, Christopher M. , Reddy, Yogesh N.V. , Rosano, Giuseppe , Saldarriaga, Clara , Udelson, James E. , Urbinati, Alessia , Vlajnic, Vanja , Xing, Aiwen, Patel, Mahesh J., Zannad, Faı̈ez , Lam, Carolyn S P , Senni, Michele , Voors, Adriaan A , Zannad, Faiez , Nishimura, Rick , Butler, Javed , Mentz, Robert J , Teixeira, Pedro P, Ezekowitz, Justin A. , Lam, Carolyn S.P. , Lindenfeld, JoAnn , Ponikowski, Piotr , Senni, Michele , Voors, Adriaan A.

European Heart Journal | August 15, 2025 | Volume: 47 | Issue: 6 | Pages: 683-697

10.1093/eurheartj/ehaf655 | PMID 40884032 Get It

Abstract Background and Aims In the VICTOR trial (NCT05093933), vericiguat was neutral for the primary composite endpoint of cardiovascular death or hospitalization for heart failure (HF). VICTOR was powered to independently assess cardiovascular death. This study reports detailed analysis on the effects of vericiguat on mortality. Methods VICTOR, a double-blind, placebo-controlled, randomized trial, enrolled 6105 ambulatory patients with HF and reduced ejection fraction (HFrEF) without recent worsening and randomized them to vericiguat or placebo. The main outcome for this analysis was the pre-specified secondary endpoint of cardiovascular death. All-cause death, sudden cardiac death, and death related to HF were also assessed. Results Over a median of 19.7 months (inter-quartile range 14.6–25.4), cardiovascular deaths occurred in 292 patients (5.7 deaths per 100 patient-years) and 346 patients (6.8 deaths per 100 patient-years) in the vericiguat and placebo groups, respectively (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.71–0.97; P = .020). Risk of death from any cause was lower with vericiguat vs placebo (377 [7.3 deaths per 100 patient-years] vs 440 [8.6 deaths per 100 patient-years]; HR 0.84, 95% CI 0.74–0.97; P = .015). Sudden cardiac death and HF-related deaths were lower with vericiguat vs placebo (1.6 vs 2.2 events per 100 patient-years; HR 0.75, 95% CI 0.56–0.99; P = .042 and 1.7 vs 2.4 events per 100 patient-years; HR 0.71, 95% CI 0.54–0.94; P = .016, respectively). Lower mortality rates were consistent across subgroups including baseline therapy. Consistent cardiovascular and all-cause mortality benefit was seen across baseline N-terminal pro-B-type natriuretic peptide levels. Conclusions In ambulatory well-treated participants with HFrEF, vericiguat was associated with clinically meaningful reductions in the key secondary outcome of cardiovascular death, as well as all-cause mortality.
Postoperative benefits of sugammadex: A narrative review
Linn, Dustin D , Renew, J. Ross

American Journal of Health-System Pharmacy | August 15, 2025 | Volume: 83 | Issue: 5 | Pages: e183-e191

10.1093/ajhp/zxaf213 | PMID 40825049 Get It

Abstract Purpose To describe the systemic benefits of sugammadex as a reversal agent for neuromuscular blockade. Summary Sugammadex is the preferred reversal agent for neuromuscular blockade as recommended in guidelines from the American Society of Anesthesiology. This recommendation is primarily based on a faster time to recovery from neuromuscular blockade as compared to that seen with neostigmine. Systemic adverse effects of neostigmine are often mitigated by the administration of glycopyrrolate. However, glycopyrrolate is an antimuscarinic agent that may be associated with its own adverse effects when used as part of a reversal strategy for neuromuscular blockade. This review describes the potential systemic benefits of sugammadex, compared to an acetylcholinesterase/anticholinergic strategy, related to postoperative nausea and vomiting, urinary retention, bowel recovery, and cognitive dysfunction while also discussing its role in enhanced recovery after surgery protocols. Conclusion Sugammadex is associated with a reduction in systemic effects when compared to combinations of neostigmine and glycopyrrolate. Further research is needed on important clinical and economic outcomes associated with a reduction in these adverse effects.
Administrative overload harms patient care
Arab, Sammy , Chhatwal, Karanjot , Khan, Hamaad Ahmad , Rosen, Stuart D, Arab, Sammy

BMJ | August 15, 2025 | Volume: 390 | Issue: No issue available | Pages: r1747

10.1136/bmj.r1747 | PMID 40816729 Get It

Beyond Post hoc Explanations: A Comprehensive Framework for Accountable AI in Medical Imaging Through Transparency, Interpretability, and Explainability
Singh, Yashbir , Hathaway, Quincy A. , Keishing, Varekan, Salehi, Sara , Wei, Yujia , Vera-Garcia, Diana V. , Kh, Almurtadha Mula, Quaia, Emilio , Vera-Garcia, Diana V , Quaia, Emilio , Andersen, Jesper B , Singh, Yashbir , Hathaway, Quincy A , Salehi, Sara , Wei, Yujia , Horvat, Natally , Choudhary, Ashok, Andersen, Jesper B.

Bioengineering | August 15, 2025 | Volume: 12 | Issue: 8 | Pages: 879

10.3390/bioengineering12080879 | PMID 40868392 Get It

The integration of artificial intelligence (AI) in medical imaging has revolutionized diagnostic capabilities, yet the black-box nature of deep learning models poses significant challenges for clinical adoption. Current explainable AI (XAI) approaches, including SHAP, LIME, and Grad-CAM, predominantly focus on post hoc explanations that may inadvertently undermine clinical decision-making by providing misleading confidence in AI outputs. This paper presents a systematic review and meta-analysis of 67 studies (covering 23 radiology, 19 pathology, and 25 ophthalmology applications) evaluating XAI fidelity, stability, and performance trade-offs across medical imaging modalities. Our meta-analysis of 847 initially identified studies reveals that LIME achieves superior fidelity (0.81, 95% CI: 0.78–0.84) compared to SHAP (0.38, 95% CI: 0.35–0.41) and Grad-CAM (0.54, 95% CI: 0.51–0.57) across all modalities. Post hoc explanations demonstrated poor stability under noise perturbation, with SHAP showing 53% degradation in ophthalmology applications (ρ = 0.42 at 10% noise) compared to 11% in radiology (ρ = 0.89). We demonstrate a consistent 5–7% AUC performance penalty for interpretable models but identify modality-specific stability patterns suggesting that tailored XAI approaches are necessary. Based on these empirical findings, we propose a comprehensive three-pillar accountability framework that prioritizes transparency in model development, interpretability in architecture design, and a cautious deployment of post hoc explanations with explicit uncertainty quantification. This approach offers a pathway toward genuinely accountable AI systems that enhance rather than compromise clinical decision-making quality and patient safety.
Performance of Creatinine and Cystatin C-Based Equations to Estimate Glomerular Filtration Rate Among Patients With Heart Failure
Roth, John , Lieske, John C. , Arruda‐Olson, Adelaide M. , Herrmann, Joerg , McCallum, Wendy , Larson, Timothy S., Rule, Andrew D. , Rule, Andrew D , Titan, Silvia M , Lieske, John C , Roth, John , Herrmann, Sandra M. , Titan, Silvia

Circulation: Heart Failure | August 15, 2025 | Volume: 18 | Issue: 10 | Pages: No page available

10.1161/circheartfailure.125.013014 | PMID 40814784 Get It

BACKGROUND: The performance of estimated glomerular filtration rate (eGFR) among patients with heart failure (HF) may be worse than in the general population due to a higher prevalence of confounding factors affecting creatinine and cystatin C. Studies in this area are scarce and not stratified by type of HF. We evaluated the performance of current creatinine and cystatin C equations (eGFRcr, eGFRcys, and eGFRcrcys) compared with measured GFR (mGFR) among patients with HF stratified by ejection fraction. METHODS: We pulled data on Mayo Clinic patients with an mGFR performed for clinical indications from 2011 to 2023, with serum creatinine and cystatin C measured within 7 days and an echocardiogram performed up to 1 year before the mGFR date. HF was identified by the presence of International Classification of Diseases codes within 1 year before the mGFR and subgrouped into ejection fraction (EF) ≥50% (HFEF≥50%, n=182) or <50% (HFEF<50%, n=115) and compared with no-HF controls (n=1871). CKD-EPI (and EKFC) eGFRcr, eGFRcys, and eGFRcrcys equations were calculated and compared for bias (mGFR minus eGFR) and accuracy (1-P30, proportion of people with ≥30% difference between eGFR and mGFR). CIs were generated by bootstrapping. RESULTS: The HF groups were characterized by older age, higher proportion of males, more diabetes, higher creatinine, and higher cystatin C than controls. In terms of bias, eGFRcr overestimated mGFR to a greater extent in both HF groups compared with controls, whereas eGFRcys and eGFRcrcys showed similar bias in both HF groups and controls. In the HF groups, cystatin C-based equations were more accurate than eGFRcr, particularly within HFEF<50% (1-P30 of 28% and 34% for CKD-EPI eGFRcys and eGFRcrcys, respectively, versus 60% for eGFRcr), whereas eGFRcrcys was more accurate in controls. The CKD-EPI and EKFC equations were overall convergent, showing similar results. CONCLUSIONS: Among patients with HF, eGFRcr demonstrates inferior performance (more bias and less accuracy) compared with cystatin C-based eGFRs, with this effect being more pronounced in those with HFEF<50%.
20-year Trends in Clinical and Research Roles of Women Physicians in Thyroid Eye Disease
McInnis-Smith, Kerri M., Kraker, Jessica A. , Langlais, Blake, Palacios, Victoria J. , McInnis‐Smith, Kerri , Ren, Yanhan , Wagner, Lilly H.

Journal of Academic Ophthalmology | August 15, 2025 | Volume: 17 | Issue: 2 | Pages: No page available

10.62199/2475-4757.1287 Get It

Purpose: To evaluate the role of women physicians in thyroid eye disease (TED) research and clinical care and describe relevance for academic medicine and patient access. Methods: A cross-sectional study of TED-related publications indexed on PubMed in 2000, 2010, and 2020, and of completed or currently active clinical trials was conducted. Author, journal, and principal investigator (PI) characteristics were noted. Author/PI gender was determined from institutional profile or subsequently via a previously described Google-based algorithm. American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS), American Board of Ophthalmology (ABO), and American Thyroid Association (ATA) information was obtained via direct communication. Trends in participation of men and women were evaluated. Results: A total of 444 manuscripts (61 from 2000; 117 from 2010; 266 from 2020) were included. The percentage of women as first and senior authors increased from 2000 to 2020 (p < 0.0001 and p = 0.0003, resp.). First author gender distribution was near equal in 2020 (52.6% men, 47.4% women [p = 0.39]), whereas senior authors remained mostly men (68.0% men, 32.0% women [p < 0.0001]). As of 2020, the gender imbalance of senior authors was greater on multidisciplinary author teams (74.8% men, 25.2% women) compared with single specialty author teams (62.2% men, 37.8% women). Of the 98 TED-related clinical trials included, 34 had women PIs (35%). The percentage of women as members in ASOPRS, ABO, and ATA all increased significantly from 2000 to 2020, but remained disproportionately men in 2020 (all p < 0.0001). Conclusion: Gender-based discrepancies persist in TED research, especially among senior authors, who determine research direction, and on multidisciplinary teams, which reflect the preferred model of care. Further efforts are required to determine whether these findings affect patients with TED.